Uniphar Durbin Ireland Limited and TFF Pharmaceuticals, Inc. announced the opening of an Expanded Access Program (EAP) enabling patients access to TFF-VORI in the United States, Australia, United Kingdom, Canada and select countries in Europe.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | +1.57% | +10.23% | -72.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-72.36% | 6.01M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- TFFP Stock
- News TFF Pharmaceuticals, Inc.
- Uniphar Durbin Ireland Limited and TFF Pharmaceuticals, Inc. Announce Opening of Expanded Access Program for Voriconazole Inhalation Powder for Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections